ClinicalTrials.gg
CompletedNCT02616250MOSAICUpdated Feb 18, 2021Results posted

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

A Phase 4 interventional study of Brimonidine 0.33% gel (Br) and CD07805/47 (Br) placebo gel in Rosacea, sponsored by Galderma R&D. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.

Enrollment
7th of 11
190 · median 205
Started
2015
the only one that year
Phase 4
4 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
8 of 11
Galderma R&D

Among the 11 studies testing brimonidine in Rosacea, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 4, and was the 9th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing brimonidine in Rosacea as a file.
02

Study summary

The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.

03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Male or female subjects age 18 years or older;
  2. Subjects with a minimum of 15 but not more than 70 inflammatory lesions (papules and pustules) of rosacea on the face;
  3. Subjects with moderate or severe diffuse persistent facial erythema of rosacea (scored 3 or 4 according to Clinician's Erythema Assessment [CEA]);
  4. Subjects with moderate or severe papulopustular rosacea (scored 3 or 4 according to the Investigator's Global Assessment [IGA]);
  5. Female subjects of with a negative urine pregnancy test (UPT);
  6. Female subjects of childbearing potential must practice a highly effective method of during the study;
  7. Females subjects of non-childbearing potential;

Main Exclusion Criteria:

  1. Subjects with particular forms of rosacea or other concomitant facial dermatoses that may be confounded with rosacea;
  2. Subjects with more than 2 nodules of rosacea on the face;
  3. Subjects with any uncontrolled chronic or serious disease or medical condition that may either interfere with the interpretation of the clinical trial results, or with optimal participation in the study or would present a significant risk to the subject;
  4. Subjects with known or suspected allergies or sensitivities to any component of the and non-investigational products, including the active ingredients brimonidine or salts of brimonidine like brimonidine tartrate and ivermectin;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream

    Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks. Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks.

    Drug: Brimonidine 0.33% gel (Br) · Other: CD07805/47 (Br) placebo gel · Drug: Ivermectin 1% cream (IVM)

  • Placebo comparator
    CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream

    Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.

    Other: CD07805/47 (Br) placebo gel · Other: CD5024 (IVM) placebo cream

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA):

    Percentage of patients defined as success as per scores of IGA; ie: clear (score=0) or almost clear (score=1)

    Time frame: week 12/Hour 3

07

Results

Posted Oct 19, 2017

Participant flow

Participant flow — Overall Study
MilestoneBrimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% CreamCD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream
Started9595
Completed8586
Not completed109

Outcome measures

PrimaryEfficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA):

Percentage of patients defined as success as per scores of IGA; ie: clear (score=0) or almost clear (score=1)

Time frame:
week 12/Hour 3
Reported as:
Count of participants · Participants
Efficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA):
ParticipantsBrimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% CreamCD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream
Efficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA):5335

Adverse events

Collected over All AEs occurring after subject's consent and during the study were recorded; 3 months for a given subject 10 months for the study; ie: from first subject enrolled until last visit of last subject enrolled. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% Cream0/95 (0%)5/95 (5.3%)8/95 (8.4%)
CD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream0/95 (0%)1/95 (1.1%)13/95 (13.7%)
Most frequent serious events
Most frequent serious events
EventBrimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% CreamCD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream
atrial fibrillationCardiac disorders1/950/95
Biliary cirrhosis primaryHepatobiliary disorders1/950/95
PneumoniaInfections and infestations0/951/95
Type 2 diabetes mellitusMetabolism and nutrition disorders1/950/95
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/950/95
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/950/95
Most frequent other events
Most frequent other events
EventBrimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% CreamCD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo Cream
Upper respiratory tract infectionInfections and infestations2/955/95
nasopharyngitisInfections and infestations3/955/95
erythemaSkin and subcutaneous tissue disorders3/951/95
rosaceaSkin and subcutaneous tissue disorders0/952/95

Baseline characteristics

Age, Continuous
Age, Continuous(years)Brimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% CreamCD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo CreamTotal
Mean51.0 ± 14.848.0 ± 13.650.0 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)Brimonidine 0.33% Gel / CD07805/47 (Br) + Ivermectin 1% CreamCD07805/47 (Br) Placebo Gel + CD5024 (IVM) Placebo CreamTotal
Female282553
Male6770137
08

Study locations

13 sites
  • Fort Smith, Arkansas, United States
  • Rogers, Arkansas, United States
  • Sacramento, California, United States
  • Orlando, Florida, United States
  • Omaha, Nebraska, United States
  • New York, New York, United States
  • Pflugerville, Texas, United States
  • Surrey, British Columbia, Canada
  • Markham, Ontario, Canada
  • Peterborough, Ontario, Canada
  • Richmond Hill, Ontario, Canada
  • Waterloo, Ontario, Canada
  • Windsor, Ontario, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2015
First posted
Nov 26, 2015
Start
Dec 2015
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results first posted
Oct 19, 2017
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02616250
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Nov 26, 2015
Start date
Dec 2015
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
Oct 19, 2017
Last update
Feb 18, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brimonidine · Ivermectin

Start the discussion